Abingworth Bioventures 9 LP
Abingworth Bioventures 9 LP is a private equity fund based in Washington, District of Columbia. According to its most recent Form D, filed Dec 19, 2025, it has sold $320,300,000 of interests to 29 investors since its first sale in Dec 2023. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Jeremy Anderson; David Lobe; Christina Gibbs.
- Total raised
- $320,300,000Cumulative sales reported on Form D
- Investors
- 29
- First sale
- Dec 22, 2023
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Jeremy Anderson; David Lobe; Christina Gibbs
- Latest Form D
- Dec 19, 2025
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Abingworth Bioventures 9 LP
What is the minimum investment for Abingworth Bioventures 9 LP?
Abingworth Bioventures 9 LP's latest Form D, filed Dec 19, 2025, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Abingworth Bioventures 9 LP?
Abingworth Bioventures 9 LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Abingworth Bioventures 9 LP raised?
Abingworth Bioventures 9 LP reports $320,300,000 sold from 29 investors on its Form D filed Dec 19, 2025. This is cumulative sales since the offering began, not current assets or performance.
Where is Abingworth Bioventures 9 LP based?
Abingworth Bioventures 9 LP is based in Washington, District of Columbia.
When did Abingworth Bioventures 9 LP launch?
Abingworth Bioventures 9 LP reports its first sale in Dec 2023.
Size compared with every private equity fund
Raised more than 86% of the 141 private equity funds based in District of Columbia, and more than 86% of all 9,142 that report sales.
Other funds with the same team
- Carlyle Asset-Backed Income Fund, L.P.$1.5B
- Carlyle Infrastructure Credit Fund II Note Issuer, L.P.$968M
- Carlyle Europe Partners VI - EU, S.C.Sp.$666M
- Carlyle European Direct Lending Fund$468M
- Carlyle EDLF Note Issuer, L.P.$344M
- Carlyle Flexible Credit Opportunities Feeder Fund (Parallel), L.P.$258M
- Carlyle Flexible Credit Opportunities Feeder Fund, L.P.$258M
- Carlyle Direct Lending Fund (Levered), L.P.$232M